Muparfostat exhibits additional binding affinity toward lipoprotein lipase, thereby causing severe hyperlipidemia and ultimately exacerbating hepatic steatosis and liver damage, particularly in obese individuals.[21]. Here, LPL is linked to hyperlipidemia.